Navigation Links
Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
Date:1/9/2008

MONTVALE, N.J., Jan. 9 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its subsidiary, Barr Laboratories, has initiated a challenge of the patents listed by Sanofi-Aventis U.S. LLC in connection with its Eloxatin(R) (Oxaliplatin Aqueous Solution), 5mg/mL Injectable.

Barr filed an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for a generic Eloxatin product with the U.S. Food & Drug Administration (FDA), and following FDA notification of the application's acceptance for filing, the Company notified the New Drug Application (NDA) and patent owner.

On January 4, 2008, Sanofi-Aventis U.S. LLC, Sanofi-Aventis and Debiopharm S.A. filed suit in the U.S. District Court of New Jersey to prevent the Company from proceeding with the commercialization of its product. This action formally initiates the patent challenge process under the Hatch-Waxman Act.

Eloxatin (Oxaliplatin Aqueous Solution), 5mg/mL Injectable, used in combination with infusional 5-FU/LV, is indicated for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor, and is indicated for the treatment of advanced carcinoma of the colon or rectum. The product had sales of approximately $1.1 billion in the U.S., based on IMS sales data for the 12-months ended October 2007.

About Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its pr
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Barr Confirms Patent Challenge of Focalin(R) XR
2. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
3. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
4. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
5. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
8. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
9. Odyssey Thera Granted U.S. Patent for Animal Imaging
10. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
11. iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 DTS Language Services, Inc . ... Portal for Life Science organizations who need document translations. ... matter of their documents in advance with a selection of ... of translations, often a critical factor in clinical and scientific ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... nation's dysfunctional healthcare system may undermine any progress in patient ... according to a featured speaker at this week's Digital ... Jeff Grossman, president and CEO of the University of Wisconsin ... IT in healthcare delivery. As he outlined the remaining barriers ...
... Wis. They can cost as much as buildings ... possible if the right people are involved and excited, said ... WTN Media. , ,"User ownership is absolutely essential," said Peter ... don't know the application, if they don't feel they're being ...
... research projects on his campus will get ahead by ... you. , ,"Let's get real," Santiago told listeners at ... education in Wisconsin. "(UW-Milwaukee research programs) are not competing ... their evolution." , ,Likewise, don't suggest to Santiago that ...
Cached Biology Technology:U.S. health system could undermine EHR progress 2U.S. health system could undermine EHR progress 3Healthcare leaders tell how they rally stakeholders around IT 2Why Milwaukee needs its own thriving research base 2Why Milwaukee needs its own thriving research base 3
(Date:7/9/2014)... the bladders of healthy women differ from bacteria ... according to researchers from Loyola University Chicago Stritch ... July 9, 2014, in the American Society for ... bacterial communities may play a role in female ... a common, yet poorly understood, condition with symptoms ...
(Date:7/9/2014)... Indiana state parks have helped restore the health of ... populations of white-tailed deer, a Purdue study shows. , ... of forest ecology, found that a 17-year-long Indiana Department ... parks has successfully spurred the regrowth of native tree ... , Jenkins said that while hunting may be ...
(Date:7/9/2014)... RIVERSIDE, Calif. Sexual selection refers to species, selection ... This special type of natural selection enhances opportunities to ... example. , Biologists at the University of California, Riverside ... the formation of a placenta are linked. Describing ... fish in the family Poeciliidae, the researchers found that ...
Breaking Biology News(10 mins):Hunting gives deer-damaged forests in state parks a shot at recovery 2Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4
... revealing the genetic instructions inside corn, one of the big ... most complex sequences of DNA ever analyzed, says University of ... 100 authors in the article in the journal Science ... full of confusing repeats and dead-ends that have troubled would-be ...
... , WALL, N.J., Nov. 19 BIO-key ... wireless public safety and finger-based biometric identification solutions, announced ... without any action being taken because a quorum was ... impressive 99.3% of the 35 million votes cast voted ...
... new study of maize has identified thousands of diverse genes ... allow breeders and researchers to use this genetic variation to ... easily possible before. Publishing in the Nov. 19 issue ... author are at Cornell, have identified the first map of ...
Cached Biology News:Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3BIO-key(R) Provides Update to Special Shareholder Meeting 2BIO-key(R) Provides Update to Special Shareholder Meeting 3New map of variation in maize genetics holds promise for developing new varieties 2
... Clone/PAD: ZMD.330. Immunogen: Synthetic peptide derived ... rat and mouse protein kinase C zeta ... rat and mouse PKCzeta protein. Recognizes ... not cross-react with PKCiota/lambda. Reactivity: Mouse ...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Request Info...
... Immunogen KLH-conjugated, ... acids 47-66 (PAEV-GPGAVGERTPRKKEPP) of human ... 1 (BHC110/LSD1). Quality Assurance ... Stability 2 ...
Biology Products: